-transparent.png){kind=logo}
A patient who developed retroperitoneal fibrosis on low dose continuous methysergide therapy is presented. Discontinuing the drug led to rapid clinical improvement but the patient was subsequently found to have disseminated malignant lymphoma. This may have had a synergistic effect with methysergide in producing retroperitoneal fibrosis. The patient had also previously had thyrotoxicosis but no evidence of a continuing autoimmune process was found.
Related Publications
B P Hurley, and
E B Macarthur, and
G L Utley
December 1966,
American heart journal,
B P Hurley, and
E B Macarthur, and
G L Utley
February 1987,
Lancet (London, England),
B P Hurley, and
E B Macarthur, and
G L Utley
April 1987,
Lancet (London, England),
B P Hurley, and
E B Macarthur, and
G L Utley
March 1966,
British medical journal,
B P Hurley, and
E B Macarthur, and
G L Utley
November 1966,
British medical journal,
B P Hurley, and
E B Macarthur, and
G L Utley
May 1967,
The New Zealand medical journal,
B P Hurley, and
E B Macarthur, and
G L Utley
January 1972,
Urologia internationalis,
B P Hurley, and
E B Macarthur, and
G L Utley
May 1965,
Lancet (London, England),
B P Hurley, and
E B Macarthur, and
G L Utley
May 1965,
British medical journal,
B P Hurley, and
E B Macarthur, and
G L Utley
October 2021,
Internal medicine (Tokyo, Japan),
